• Vaccine Ontology ID: VO_0011491
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: mouse
• TSA gene engineering:
  • Type: DNA vaccine construction
  • Detailed Gene Information: Click Here.
• Vector: pVAX1 (Silva et al., 2009)
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0011492
• Type: Subunit vaccine
• Status: Research
• Host Species as Laboratory Animal Model: mouse
• MAPP15 gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0000139
• Adjuvant:
  • VO ID: VO_0000142
• Immunization Route: Subcutaneous

Mouse Response

• Host Strain: BALB-c
• Vaccination Protocol: Mice were immunized by injecting 100 μg (200 μl) of plasmid DNA encoding nTSA gene by intramuscular route. As a control groups, five mice were injected with 100 μg of plasmid pVAX1LacZ (Invitrogen—USA) and with 200 μl of PBS by the same route (Silva et al., 2009).
• Challenge Protocol: After 175 days of immunization, mice in vaccinated and control groups were submitted to the challenge assay, performed by intraperitoneal injection of 500 parasites (T. b. brucei GVR 35 1.5) per animal. The period of survival, defined as the number of days after infection that the infected animals remain alive, was evaluated (Silva et al., 2009).
• Efficacy: The DNA vaccination process was able to protect 60% of mice submitted to a challenge assay with the infective form of T. brucei brucei parasites (Silva et al., 2009).

Mouse Response

• Host Strain: Swiss
• Vaccination Protocol: Swiss male mice were injected three times subcutaneously on days 1, 7 and 21 with the antigen. Antigen contained 10 μg of native p15 isolated from T. brucei brucei KETRI 2693, recombinant p15 purified from Ad-p15 infected HEK293 cells, partially purified subpellicular microtubules as a positive control (subpellicular fraction >30 kDa), or with PIPES buffer used to purify p15 as a negative control. Vaccinations included complete Freund’s adjuvant on first injection and incomplete Freund’s adjuvant on second and third injections. To test the protective potential of the recombinant viral vaccine, mice were injected intramuscularly (on days 1, 7 and 21) with 2×10^9 Ad-p15 virus particles or with control Ad-lacZ (Rasooly and Balaban, 2004).
• Challenge Protocol: Animals were challenged intraperitoneally on day 31 with 500 T. brucei brucei strain SB1 (Rasooly and Balaban, 2004).
• Efficacy: Vaccination of mice with p15 (native or recombinant) generated up to 100% protection from an otherwise lethal challenge of a heterologous strain of Trypanosoma brucei (Rasooly and Balaban, 2004).